Insider Selling: Protagonist Therapeutics Inc (PTGX) Insider Sells $17,500.00 in Stock

Protagonist Therapeutics Inc (NASDAQ:PTGX) insider David Y. Liu sold 875 shares of Protagonist Therapeutics stock in a transaction on Thursday, November 30th. The shares were sold at an average price of $20.00, for a total value of $17,500.00. Following the completion of the transaction, the insider now owns 4,697 shares in the company, valued at approximately $93,940. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink.

David Y. Liu also recently made the following trade(s):

  • On Monday, November 13th, David Y. Liu sold 7,000 shares of Protagonist Therapeutics stock. The shares were sold at an average price of $16.97, for a total value of $118,790.00.

Shares of Protagonist Therapeutics Inc (NASDAQ PTGX) traded down $0.25 on Monday, reaching $19.25. The company’s stock had a trading volume of 95,800 shares, compared to its average volume of 84,137. Protagonist Therapeutics Inc has a 52-week low of $8.00 and a 52-week high of $26.36.

Protagonist Therapeutics (NASDAQ:PTGX) last announced its earnings results on Monday, November 6th. The company reported ($0.29) EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.69) by $0.40. The company had revenue of $8.78 million for the quarter. equities analysts anticipate that Protagonist Therapeutics Inc will post -3.66 earnings per share for the current fiscal year.

Large investors have recently made changes to their positions in the company. FMR LLC increased its position in Protagonist Therapeutics by 0.4% in the 2nd quarter. FMR LLC now owns 2,528,462 shares of the company’s stock valued at $28,597,000 after buying an additional 10,264 shares in the last quarter. Vanguard Group Inc. increased its position in Protagonist Therapeutics by 3.8% in the 2nd quarter. Vanguard Group Inc. now owns 325,395 shares of the company’s stock valued at $3,680,000 after buying an additional 11,881 shares in the last quarter. Senzar Asset Management LLC bought a new stake in Protagonist Therapeutics in the 2nd quarter valued at about $3,094,000. State Street Corp increased its position in Protagonist Therapeutics by 20.9% in the 2nd quarter. State Street Corp now owns 112,474 shares of the company’s stock valued at $1,270,000 after buying an additional 19,411 shares in the last quarter. Finally, Geode Capital Management LLC increased its position in Protagonist Therapeutics by 1.9% in the 1st quarter. Geode Capital Management LLC now owns 101,218 shares of the company’s stock valued at $1,296,000 after buying an additional 1,850 shares in the last quarter. 39.68% of the stock is currently owned by institutional investors.

PTGX has been the topic of several recent analyst reports. Zacks Investment Research upgraded Protagonist Therapeutics from a “hold” rating to a “buy” rating and set a $14.00 price target on the stock in a research note on Friday, August 18th. ValuEngine upgraded Protagonist Therapeutics from a “sell” rating to a “hold” rating in a research report on Monday, August 28th. Finally, BMO Capital Markets reduced their price objective on Protagonist Therapeutics from $45.00 to $40.00 and set an “outperform” rating on the stock in a research report on Thursday, October 19th.

COPYRIGHT VIOLATION NOTICE: This news story was first posted by StockNewsTimes and is owned by of StockNewsTimes. If you are reading this news story on another site, it was illegally stolen and reposted in violation of United States and international copyright laws. The legal version of this news story can be read at https://stocknewstimes.com/2017/12/04/insider-selling-protagonist-therapeutics-inc-ptgx-insider-sells-17500-00-in-stock.html.

About Protagonist Therapeutics

Protagonist Therapeutics, Inc is a clinical-stage biopharmaceutical company with a peptide technology platform focused on discovering and developing new chemical entities (NECs) to address significant unmet medical needs. The Company’s product pipeline includes PTG-100, PTG-200 and PTG-300. Its primary focus is on developing oral peptide drugs that target biological pathways also targeted by marketed injectable antibody drugs.

Receive News & Ratings for Protagonist Therapeutics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Protagonist Therapeutics Inc and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply